Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 3/20 | 0.34 |
| ▸ | HTR1A | P08908 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952627 | 1.00 | PARP1 (0.42) | PARP1MEN1LMNATHRBBLM | |
| SCHEMBL734868 | 0.89 | PARP1 (0.53) | PARP1MEN1LMNATHRBBLM | |
| SCHEMBL29385220 | 0.89 | PARP1 (0.53) | PARP1MEN1LMNATHRBBLM | |
| SCHEMBL6293516 | 0.85 | PARP1 (0.37) | PARP1MEN1LMNATHRBBLM | |
| SCHEMBL17842806 | 0.77 | ERN1 (0.33) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL18182086 | 0.77 | ERN1 (0.39) | PARP1MEN1LMNATHRBBLM | |
| SCHEMBL1253612 | 0.77 | KDM4E (0.53) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL27371497 | 0.76 | PARP1 (0.41) | PARP1MEN1LMNATHRBBLM | |
| SCHEMBL4992978 | 0.76 | MEN1 (0.44) | PARP1MEN1LMNATHRBBLM | |
| SCHEMBL28191044 | 0.76 | PARP1 (0.38) | PARP1NAMPTKDM4ECLK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190111044-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | Prosetta Antiviral, Inc. | 2019-04-18 | — | — | US | disclosed |
| US-10195189-B2 | 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds | Prosetta Antiviral, Inc. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| CN-104876955-B | Arginase inhibitor and its treatment use | 马尔斯公司 | 2018-11-23 | — | — | CN | disclosed |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| US-9994594-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-28 | — | — | US | disclosed |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| US-9518022-B2 | Anti-HIV compounds | PROSETTA ANTIVIRAL INC. (US) | 2016-12-13 | — | — | US | disclosed |
| WO-2016172191-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1355909-A2 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-10-29 | — | — | EP | disclosed |
| CN-1379761-A | Fused indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESAERCH LTD (GB) | 2002-11-13 | — | — | CN | disclosed |
| WO-2002062795-A9 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002062795-A2 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | WO | disclosed |
| EP-1202964-A1 | CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001012602-A1 | CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2001-02-22 | — | — | WO | disclosed |
| WO-2001009125-A1 | NOVEL 8-CARBONYL CHROMAN DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2001-02-08 | — | — | WO | disclosed |
| WO-2001009124-A1 | 8-CARBONYL CHROMAN DERIVATIVES, PREPARATION AND THERAPIC USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2001-02-08 | — | — | WO | disclosed |
| WO-2001009112-A1 | NOVEL 8-CARBONYL CHROMAN DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190111044-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | MAVS, EIF2AK2, POLRMT | PARP1 169/4885MEN1 3715/4885LMNA 3070/4885 |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | PARP1 3119/4885MEN1 2806/4885LMNA 3157/4885 |
| US-10195189-B2 | 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds | MAVS, EIF2AK2, POLRMT | PARP1 169/4885MEN1 3715/4885LMNA 3070/4885 |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | PARP1 3119/4885MEN1 2806/4885LMNA 3157/4885 |
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | MAVS, EIF2AK2, POLRMT | PARP1 169/4885MEN1 3715/4885LMNA 3070/4885 |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | GSK3B, GSK3A, PYGB | PARP1 1974/4885MEN1 3826/4885LMNA 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.